Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder in children and can affect mental health throughout their lifetime. Take this course to learn about new medications in the pipeline that may offer better outcomes for our patients, and how to help patients choose the best pharmacologic and non-pharmacologic treatments.

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Review epidemiology, pathophysiology, symptoms, and diagnosis of ADHD in children and adolescents.
2. Define non-pharmacologic and pharmacologic treatment of ADHD in children and adolescents.
3. Discuss patient specific factors and medication adverse effects to consider when choosing drug therapy for ADHD in children and adolescents.
4. Describe new pharmacologic agents in the pipeline for ADHD.  

Katherine Greenhill, PharmD, BCPPS
Pediatric Clinical Pharmacist
Duke University Hospital

Katherine Greenhill has no relevant financial relationships to disclose.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: June 1, 2022
Planned Expiration Date: June 1, 2025

Copyright 2022, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

RV2-3.24